Personalized mRNA Vaccine Improves Relapse-Free Survival in Melanoma Patients

A clinical trial demonstrated that a personalized mRNA vaccine, combined with pembrolizumab, significantly improved relapse-free survival for melanoma patients. The vaccine works by providing the immune system with a 'blueprint' to target hidden cancer cells. This larger study, involving 1,000 participants, met its primary endpoint, suggesting a dramatically better outcome and potentially a new, effective treatment strategy.